Aristea Therapeutics to Present at the 2019 BIO Investor Forum
SAN DIEGO, Oct. 15, 2019 /PRNewswire/ -- Aristea Therapeutics (Aristea), a clinical-stage immunology focused drug development company developing novel therapies to treat serious inflammatory diseases, today announced that the Company will present at the 2019 BIO Investor Forum being held October 22-23, 2019 in San Francisco, CA. Dr. James Mackay, President and CEO of Aristea, will present at the conference and meet with investors.
Presentation Details:
Date/Time: October 23, 2019, 9:30 am PT Location: The Westin St. Francis, San Francisco, CA
About Aristea Therapeutics
Aristea Therapeutics (Air-iss-tay-uh) is a clinical-stage immunology focused drug development company developing novel therapies to treat serious inflammatory diseases. The Aristea team is leveraging its broad industry expertise and proven success in drug development to form synergistic partnerships and build a pipeline of novel drugs. Aristea's lead program, RIST4721, is currently in Phase 2 clinical development. Aristea is headquartered in San Diego, CA. To learn more, please visit www.aristeatx.com.
Cybin Inc. (Cboe CA:CYBN) ("Cybin" or the "Company"), a clinical-stage biopharmaceutical company committed to revolutionizing mental healthcare by developing new and innovative next-generation psychedelic-based treatment options, today announced...
ThinkCX Technologies Inc., a pioneer in advanced data analytics for the telecom sector, today announced the US launch of its groundbreaking product, Mobile SwitchInsight, set to redefine market intelligence capabilities for US wireless carriers....
Kore Digital Mining Ltd, a UK based Bitcoin mining company, announces that effective 1st May 2024, an additional 14 PH/s mining capacity will be added to its existing infrastructure.
This additional capacity will be provided by a major Bitcoin...
Orezone Gold Corporation (the "Company" or "Orezone") is pleased to provide drill results from its Bomboré Gold Mine located in central Burkina Faso. The results are part of Orezone's ongoing infill and advanced grade control program which was...
Ziosoft, a pioneer in 3D/4D AI medical visualization, will feature its unique REVORAS-enabled thoracic surgical planning capabilities at the annual American Association of Thoracic Surgeons (AATS) conference being held April 27 - 29, 2024 in Toronto,...
Global entertainment platform delivers Revenue of $79 million and strong profitability, including Net Income of $3.3 million up 33% YoY and Total Adjusted EBITDA Margin(1) of 40.5% up more than 300 basis points YoY.IMAX system installations climb...
